If Genmab's drug tisotumab vedotin is approved in the US in October as expected, the firm will take on its own sales and marketing for the first time.
The Danish biotech company is currently expanding its workforce to prepare for participating in commercial activities with US company Seagen, formerly Seattle Genetics, with which it shares the rights for tisotumab vedotin equally.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.